意义未明的克隆性造血:2型糖尿病及相关并发症的新兴危险因素
本文综述了意义未明的克隆性造血(CHIP)作为2型糖尿病及相关并发症新兴危险因素的研究进展。CHIP由髓系白血病相关体细胞突变驱动,与多种年龄相关疾病尤其是心血管疾病风险升高相关,新证据提示其也可能参与2型糖尿病及其部分并发症的发病机制。综述强调需进一步研究以明确该关系并探索其在个性化预防策略中的潜在价值。
要点
- CHIP由髓系白血病相关体细胞突变驱动,可加剧炎症反应。
- CHIP与多种年龄相关疾病风险升高相关,尤其是心血管疾病。
- 新证据提示CHIP可能参与2型糖尿病及其部分并发症的发病机制。
核心结论
- CHIP可能作为2型糖尿病的新型危险因素,但需进一步研究以明确该关系及其在个性化预防中的潜在价值。
研究设计与样本
- 综述,总结CHIP与2型糖尿病关系的现有知识。
主要发现
- CHIP由髓系白血病相关体细胞突变驱动,可加剧炎症反应,与多种年龄相关疾病风险升高相关,尤其是心血管疾病。
- 新证据提示CHIP可能参与2型糖尿病及其部分并发症的发病机制。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文强调需进一步研究以明确CHIP与2型糖尿病的关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The accumulation of acquired somatic mutations is a natural consequence of ageing, but the pathophysiological implications of these mutations beyond cancer are only beginning to be understood. Most somatic mutations are functionally neutral, but a few may confer a competitive advantage to a stem cell, driving its clonal expansion. When such a mutation arises in haematopoietic stem cells, it leads to clonal haematopoiesis, in which a significant proportion of blood cells originate from the mutant stem cell and share the same mutation. Clonal haematopoiesis of indeterminate potential (CHIP), a specific subset of clonal haematopoiesis driven by myeloid leukaemia-related somatic mutations, has been linked to a higher risk of various age-related conditions, particularly CVD, by exacerbating inflammatory responses. Emerging evidence suggests that CHIP may also contribute to the pathogenesis of type 2 diabetes and some of its complications. This review synthesises current knowledge on CHIP and its potential as a novel risk factor for type 2 diabetes, highlighting the need for further research to clarify this relationship and to explore its potential value in developing personalised preventive care strategies for type 2 diabetes and related conditions.
引用
- Zuriaga MA, Fuster JJ. Clonal haematopoiesis of indeterminate potential: an emerging risk factor for type 2 diabetes and related complications. Diabetologia. 2025. PMID: 40064675. doi:10.1007/s00125-025-06393-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。